{"links":{"html":"https://www.erudio.com/reports/magnetismm-6-nct05623020","json":"https://www.erudio.com/reports/magnetismm-6-nct05623020.json","markdown":"https://www.erudio.com/reports/magnetismm-6-nct05623020.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"magnetismm-6-05623020"}},"request":"https://www.erudio.com/contact?report=magnetismm-6-05623020"},"offer":{"cited_commentary_sources":61,"verified_hcp_statements":326,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":23,"optional":true,"price_per_verified_person_usd":15,"price_usd":345,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"magnetismm-6-nct05623020"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=magnetismm-6-05623020","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/magnetismm-6-nct05623020","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-24T12:31:32.013371Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":1},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Part 1 Dose Limiting Toxicity"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":3,"title":"Primary endpoint: Part 2: Progression free survival per IMWG"},{"claim_count":4,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":4,"title":"Primary endpoint: Part 2: Minimal Residual Disease negative CR rate"},{"claim_count":13,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":8,"title":"Secondary endpoints"},{"claim_count":13,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":13,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":20,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":12,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":18,"coverage":"discussed","id":"A1","source_count":10,"title":"Finite duration, de-escalation and the possibility of treatment-free time"},{"claim_count":8,"coverage":"discussed","id":"A2","source_count":7,"title":"Infection prevention and the continuing supportive-care burden"},{"claim_count":18,"coverage":"discussed","id":"A3","source_count":7,"title":"Earlier-line immune rationale, long-term ambitions and the threshold for added benefit"},{"claim_count":14,"coverage":"discussed","id":"A4","source_count":5,"title":"Tailoring intensity, debulking and patient-specific alternatives"},{"claim_count":13,"coverage":"discussed","id":"A5","source_count":3,"title":"Alternative induction research, later CAR-T and access-dependent pathways"},{"claim_count":31,"coverage":"discussed","id":"A6","source_count":7,"title":"Dosing convenience, outpatient readiness and patient support"},{"claim_count":10,"coverage":"discussed","id":"A7","source_count":5,"title":"MRD-guided care, assay access and unresolved maintenance decisions"}],"counts":{"cited_sources":61,"claims_by_expression_type":{"comparison":30,"experience":16,"interpretation":60,"opinion":46,"primary_context":9,"question":28,"restatement":39,"uncertainty":20,"unspecified":78},"claims_by_kind":{"attributed_opinion":25,"counterview":1,"interpretation":27,"limitation":2,"source_observation":271},"clinician_statements":132,"evidence_units":192,"findings":8,"people_cited":32,"people_identity_verified":23,"people_total":33,"screened_sources":131,"verified_claims":326},"depth":"rich","findings_index":[{"id":"F1","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":11},"has_counterview":true,"limitations":2,"links":{"context":5,"support":16},"ma_question":true,"named_voices":5,"passages":12,"sources":7,"sources_by_kind":{"commentary":3,"media":4}},"title":"Finite treatment is a condition of attractiveness for some clinicians, not an established option"},{"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":3,"views":4},"has_counterview":true,"limitations":2,"links":{"context":3,"support":12},"ma_question":true,"named_voices":4,"passages":5,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Comparator relevance became an explicit clinical question"},{"id":"F3","structure":{"claims":19,"claims_by_group":{"comparisons":3,"experience":4,"questions":4,"restated":5,"views":3},"has_counterview":true,"limitations":3,"links":{"context":16,"support":26},"ma_question":true,"named_voices":7,"passages":17,"sources":10,"sources_by_kind":{"commentary":3,"media":7}},"title":"Manageable acute toxicity does not settle the cumulative infection question"},{"id":"F4","structure":{"claims":17,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":1,"views":12},"has_counterview":true,"limitations":3,"links":{"context":10,"support":22},"ma_question":true,"named_voices":6,"passages":10,"sources":6,"sources_by_kind":{"commentary":2,"media":4}},"title":"Early activity generates substantial optimism, but durability and comparative benefit remain separate questions"},{"id":"F5","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":5,"restated":5,"views":3},"has_counterview":true,"limitations":3,"links":{"context":8,"support":22},"ma_question":true,"named_voices":3,"passages":14,"sources":7,"sources_by_kind":{"commentary":1,"media":6}},"title":"MRD is discussed as a route to personalization, not a ready-made stopping rule"},{"id":"F6","structure":{"claims":17,"claims_by_group":{"comparisons":2,"experience":1,"questions":3,"restated":2,"views":9},"has_counterview":true,"limitations":2,"links":{"context":4,"support":20},"ma_question":true,"named_voices":4,"passages":11,"sources":5,"sources_by_kind":{"commentary":1,"media":4}},"title":"Patient selection includes reasons to withhold intensity, not only reasons to add treatment"},{"id":"F7","structure":{"claims":16,"claims_by_group":{"comparisons":1,"experience":0,"questions":5,"restated":5,"views":5},"has_counterview":true,"limitations":3,"links":{"context":3,"support":18},"ma_question":true,"named_voices":7,"passages":14,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Sequencing and replacement strategies remain conditional research questions"},{"id":"F8","structure":{"claims":20,"claims_by_group":{"comparisons":3,"experience":2,"questions":2,"restated":3,"views":10},"has_counterview":true,"limitations":2,"links":{"context":14,"support":30},"ma_question":true,"named_voices":3,"passages":14,"sources":4,"sources_by_kind":{"media":4}},"title":"Monthly dosing is not the same as a low-burden or universally outpatient program"}],"medical_affairs_question":"What finite-course evidence would make the regimen attractive without replacing an efficacy advantage with an unacceptable risk of earlier relapse?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Finite duration: efficacy is the reason to test less treatment"},{"id":"section-2","level":2,"title":"Comparator relevance: historical DRd descriptions and the DVRd update answer different questions"},{"id":"section-3","level":2,"title":"Safety: infection remains consequential after the step-up period"},{"id":"section-4","level":2,"title":"Activity and biological rationale: strong promise without a demonstrated long-term comparative gain"},{"id":"section-5","level":2,"title":"MRD: measurement, prognosis and treatment decisions are not interchangeable"},{"id":"section-6","level":2,"title":"Selection: reasons to reduce intensity belong beside reasons to use powerful therapy"},{"id":"section-7","level":2,"title":"Sequencing and research alternatives: preserve the conditions before inferring a pathway"},{"id":"section-8","level":2,"title":"Delivery: convenience requires a functioning care system"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Part 1 Dose Limiting Toxicity"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T2","label":"Primary endpoint: Part 2: Progression free survival per IMWG"},{"findings":[{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":2}],"id":"T3","label":"Primary endpoint: Part 2: Minimal Residual Disease negative CR rate"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":8},{"id":"F5","shared_claims":1}],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F3","shared_claims":2},{"id":"F6","shared_claims":11},{"id":"F8","shared_claims":1}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":8}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":17},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-24T12:31:32.013371Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-24T14:32:58Z","record_hash":"a76bd76481dc099cf311a343006f68fcc1fe8a4bf2f9c8ba07afc27de16d618b","release_hash":"958aa5e54435b5f799861a9d6aa3019c1bd96cc67423a25e4eb1d2a4a608e850","report_id":"erudio-nct05623020","run_id":"eec52929-d908-4e48-bf40-c6ba87cc7c41","schema_version":"5.0","slug":"magnetismm-6-05623020","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"MagnetisMM-6 asks whether elranatamab with daratumumab and lenalidomide improves disease control over a daratumumab-based quadruplet in transplant-ineligible patients with newly diagnosed multiple myeloma. Clinicians in the sources reviewed for this edition question comparator relevance, and some make treatment attractiveness conditional on duration. Early activity draws enthusiasm in their commentary, while prolonged treatment draws scrutiny. Durability, comparative benefit and the possibility of finite treatment remain open.","meta_description":"131 sources screened · 326 verified statements (132 from speakers with a confirmed clinical role) from 61 sources · 8 findings. Updated Oct 24, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-e09ded9343d398b164a3-4a964957","claim-6c259a96bbdcdb50ff41"],"id":"F2","paraphrase":"An X discussion asked whether Dara-VRd rather than Dara-Rd should be the phase 3 comparator for the elranatamab combination.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"unavailable"},"source_channel":"x_thread","source_date":"2025-09-17","title":"Comparator relevance became an explicit clinical question"},{"cited_claim_ids":["claim-4b6700c3f5629b9ff735"],"id":"F4","paraphrase":"An X post requested MRD findings and infection data with further follow-up of the elranatamab triplet.","publication_caveats":["The discussion includes posts on both dates; the date of the individual cited post is not stated."],"source_channel":"x_thread","source_date":"2025-05-30","title":"Early activity generates substantial optimism, but durability and comparative benefit remain separate questions"}]},"publication":{"approved_at":"2026-10-24T14:32:58Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":131},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 6 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","422 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition do not represent all HCPs or establish how common any opinion is. Reposts, organizational reporting and multiple media versions of the same discussion should not be counted as independent clinician agreement.","Relevant discussions that do not name the trial or use different terminology may be missing. One social discussion was inaccessible, and portions of several long recordings were not fully evaluated, so less prominent views may be absent.","Some recordings do not identify who voiced the relevant passage. Those views remain unnamed even when a program lists recognizable participants.","No full protocol or trial-results publication was available to reconcile the reported efficacy, safety, denominator and follow-up differences. Reported numbers are what the cited speakers or organizations said.","Earlier descriptions of a DRd comparator and later descriptions of DVRd are preserved in their own temporal context. Publication dates do not establish the date of a design decision or a change in an individual's opinion.","Favorable response, tolerability and biological-rationale comments do not establish randomized comparative benefit, validated MRD-guided stopping or a preferred finite treatment duration.","Class-wide experience, individual patient experience, other frontline regimen choices and sequencing hypotheses are distinguished from observations made specifically in MagnetisMM-6. Proposed alternatives to current induction remain research questions, not established treatment replacements.","Raffaele Di Giacomo's clinical role is not stated in the sources reviewed; the author's questions should not be treated as an additional confirmed HCP endorsement."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":7,"other":0,"podcast":5,"publication":0,"registry":0,"regulatory":0,"x_thread":36,"x_video":0,"youtube":13},"by_evidence_role":{"commentary":61},"count":61,"evidence_window":{"end":"2026-10-12","start":"2023-02-19"},"retrieval_snapshot":"2026-10-24T05:15:48.148954Z","timeline":[{"count":1,"week":"2023-W07"},{"count":1,"week":"2023-W08"},{"count":1,"week":"2023-W33"},{"count":1,"week":"2025-W18"},{"count":4,"week":"2025-W21"},{"count":2,"week":"2025-W22"},{"count":4,"week":"2025-W23"},{"count":7,"week":"2025-W24"},{"count":6,"week":"2025-W25"},{"count":2,"week":"2025-W26"},{"count":1,"week":"2025-W27"},{"count":2,"week":"2025-W28"},{"count":1,"week":"2025-W29"},{"count":1,"week":"2025-W31"},{"count":2,"week":"2025-W32"},{"count":2,"week":"2025-W36"},{"count":2,"week":"2025-W37"},{"count":6,"week":"2025-W38"},{"count":1,"week":"2025-W40"},{"count":2,"week":"2025-W41"},{"count":2,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W02"},{"count":2,"week":"2026-W15"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W26"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W42"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT05623020:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05623020:context","quote_policy":"short_quote_link_out"},{"id":"openfda:aa044060-5b4b-4692-bf0f-9a50e140b10e:20260514","quote_policy":"short_quote_link_out"},{"id":"openfda:1b2716cf-24b4-4157-a218-58ede63917bd:20260527","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3lrqffynbhk2l","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-f5a7rg43t2cwqdmxw6e4tnkm-3lrfkranyye2r","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-f5a7rg43t2cwqdmxw6e4tnkm-3ls4psuyaeo2z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-n3qfcn6ycblg3brqsbnkbc23-3lpycmkw5r22i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3ly6xe3os272t","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-oqnnwbtbw6endp32s4zkfcub-3ltew6dhe4s2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vqwjwvwsp24px5yd54s4ilzi-3lyq3lpxdos24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xwwnmzvco4pljtw3zwdxvoye-3lptvr2xixk24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xwwnmzvco4pljtw3zwdxvoye-3lqdtkartnc24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xwwnmzvco4pljtw3zwdxvoye-3lqhntjzaec2g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xwwnmzvco4pljtw3zwdxvoye-3lqqoy5m5222f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:2f8956","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6b1a21","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:72eaf9","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a15e28","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b046c1","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f91923","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ff8188","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1470535726815223815:a6f48e47-66f1-4591-9fe7-f9c310f1e6fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1470591290450616330:a73bd00e-4f13-4fbf-a44d-582979368c5e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1470756462741839872:abb6a9f5-ff0b-4edc-90ea-d6f8addadeef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1500203471651446786:9c39f5d1-2389-498c-b385-0235efd9a7f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1506390384074629120:e10c276d-242a-4f53-a5d4-266f9cbbc9cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1526443695704313856:9511c543-559c-47f1-85ec-e6fc96ba0c9c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1572714726534029313:c0b1e5ce-078c-4ab1-86c4-6bf7b20d7ee6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1601646017429983232:3e072b38-b1de-40c7-ab6f-5a64823a2994","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1602658284284133377:3033aa86-3553-4fac-86cb-b0ef1c937b70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1602787586740817920:efb221f8-fa35-4f58-a6fb-330edf8d2d19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1627450455344160768:85f034be-7294-45b6-ba2d-b1e32cd3e014","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1628207553036288006:b045d07c-81e5-4fb9-9a10-642d102cb511","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665486914638454786:ff2ccc7b-5781-48f6-9414-903cbd515f7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1691199782012768256:3d65847f-869a-42ef-80a6-2964b1e755b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1691503786693697536:05719da5-d6f9-4cfb-ac49-23e8174eaaef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1691559637923873153:737757ab-5e1b-4f54-a08d-db46deb049a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1692959942469186011:1b18697c-2a22-47b9-9b14-a51d87be2377","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1708904272409030895:640801e7-af9d-4f7d-9992-231d33f8b6f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734741774533337098:72150f38-f453-4902-972a-e0d5745c7f18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1762864273381007491:8afc6c3c-77ff-483b-b933-dcc5f4478bba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1776014441995510237:45cf78a0-1fd9-4574-a35f-117bf5ae1304","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1793906122774217166:5ea161b0-dec1-4ecc-9462-c95d2e2c5442","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1794298212414615639:22318eec-6815-42c3-8998-262a6b74f145","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1801212289237848073:4c59b112-fa60-4b2b-8135-e2336860f734","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821859320939602401:8c4a772e-5713-4d4b-8225-254518c4badf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1860684276150288461:cea35447-f7d5-492e-8b68-41e662726e3f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865412281338876027:c3503401-7ca1-4692-a765-bd7377d71c80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1913114164572065808:3571735d-61da-4fe9-b476-2b5d63bac028","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925728520870760678:b90f8ee6-57c1-4186-8e64-c40e28fd4f0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925931055032197437:178790e6-19d9-4d8d-8711-d23e326df653","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928578845289926814:6ed24316-a866-4125-a09e-b67fab537063","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929933411491135802:fba0cf2f-f920-402a-b951-b0e86d6b1e9c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929933946193633508:abc92cb2-9202-4e52-8787-1ce93af08dc5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929994788545384526:3348ec0d-3ba1-4585-9945-1d864bb83e46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1930030724565828079:13dc04db-b20f-4a02-aea0-88026296fae9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1931804615064047683:cdc938fa-3da5-4c04-bf37-361fc3baa926","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1933856806004035907:78c6f170-a674-4fa9-ba8a-1e156f044019","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934181854988615964:a25da828-c9a7-4c48-b8ff-017676b1ef5e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934182979326070889:df0b2e8a-b9c6-44d9-84ca-9c5ccf86ef41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934202382990168306:4941ba2b-24db-484e-837c-3fdb8c2f8e0e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934328314128121911:35a56315-68a5-4b6c-8718-feeef38f7807","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934359683973734595:65ea2143-4cbe-4ce1-8a51-e18af067fb73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934401399229763668:ed747c15-0b9f-49b8-b74b-c9fd79f9a851","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934876219620659552:bbd09e00-a1e8-4d93-a2f6-05f4f480c87f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1935291898840723504:370df379-f74c-4703-9d8a-8429f25d59e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1936469305639440626:91b73fb4-8ec1-46b3-ba5d-ad56153fc338","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1937118541561360520:f97ca463-030c-4ab5-b387-2bcc82238df4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1942217891408990398:034ff8b6-0be4-48f9-8fac-43fb758c6e83","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1950017080914284721:bef687a8-83cf-4de6-8e96-2fdc5e03dee1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1950017305607328121:ba24c42c-02d5-41b3-aa7a-ad6ee4bf1ee7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1953396053853520054:87a2dc80-ee7f-4e73-8d39-9b994626385a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1953417959000485895:c081e2aa-a001-4fca-b6ed-71e108717e1b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960327671390286110:44db42b2-6a60-4f16-972b-c7112a5be6a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964011929044996575:0ce868bc-2f8a-456c-aba8-4caecda1d536","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964981584144031795:1d1039b7-f726-487e-8da7-812ee4253f44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1968337523106877828:05ffe056-3c78-4ac4-9fe3-b633c5434b23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1968338064327282980:34108405-727b-4df8-b0ed-28bdac372846","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1968338599792787653:9d8fd998-791e-42f5-bba6-32ba40990b87","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1968962095023542292:4dde8425-54fe-490c-8fde-90aeae8a4c33","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1968994726142488726:52fd504d-1da8-4fef-8f46-a2223df6893f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1969084128982167894:96cba3cf-b737-4fc2-a387-2654a910a736","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1970684624104726978:2ab7700e-ae46-430f-92bb-38bc8746d1f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1974076849824379192:b905a2b9-0927-481c-809e-f21669650eb5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1975548258366664769:cb73d95e-2f9f-4232-aa50-645c945eb9b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1977192496804311330:f55b7c1b-4efa-4972-8501-1ab8edc4712e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1983492642014122074:6542d935-b19c-46a8-819f-d3e0f0963f4c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1984275849651056978:a2a571c6-1e95-4215-a8f3-98ca169de11c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1985700090606964792:71f61804-1497-4e11-b608-f5fbbd044d57","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1990991281456021988:e7d86e99-60ba-4513-9642-894a433f12ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1993501212084199892:6f791e92-7908-45d5-ac41-4710d3320714","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997528103397236738:34028745-f891-4d0f-944e-00e8d50b3b88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998019989312241940:5548d736-46f4-4551-818b-03458be15a88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009048909264626120:42376fe4-2273-4992-a811-8b8ab17cc227","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2015180316751597894:09bef937-46f2-4884-86bf-002c39a6bb8c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2028552596127199454:aae7d424-dbfa-4599-b37d-13ddb7a141a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2029175842073354265:ad99585b-842a-43f1-9b9b-4d8b47b30d74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033610373731959002:edaf52f2-43c8-4cd7-b428-9be239c1d2f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037588099023385008:1eb8e057-e6b5-4bda-9413-4f7c33ea4f80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2041918660198138335:5ff22cae-c99b-49e6-9019-d127c4dd0a66","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2041948469519380567:85eb8f28-d24b-453c-9d49-0a9a7020fa08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049575229769588819:28ba7f51-5d3d-4443-b3bb-41b9140e8c46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055326840613400752:43d84bf9-572f-4a12-be25-9699edd07571","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060134524843921530:f145f52d-2abd-4010-81a0-cce8d6602783","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060420221811216826:93e65856-0947-4103-a41e-2b98a974ad7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062502793106067749:daa877f5-340b-4087-8f68-81a8ce06be11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085411132102283543:c4548f17-866b-4b4c-bc20-15acd9c2eb37","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102780644627792067:f7c3bbf9-32f5-4a04-92d6-bac5050e3e37","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102783338725450166:d01ad009-fe5b-4ef5-a76e-616a42df6190","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102787924811202646:d32c5798-83f8-45d6-bb0b-9ff91ea871a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102788185164017850:eaf57bad-5ce3-4fad-9f08-ed8bed2986ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102899187511877652:fc1268f9-9b06-49a6-96c1-fb7c9bdf2386","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103486963638755739:041eda51-5187-4049-9019-ffcc66f4dda4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109299619528159448:1f658a9a-a030-4015-8e64-ff345822671b","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:1c_qr1iiJkw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4e1CcD52Zys","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:9o587lqzpBA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FMUHT8-nS2U","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FlxqVg6tQV8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JzVmGWQElS8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:KlEEsHeeYmw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:LXEwmcEEtNU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:MXtAmrJ0JQI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:O9Gazq5VXKw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:civ3KoF5Qys","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:cjgaDCTg-gQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:edgygq1JJSA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:hX5EtJ4vde0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:jIeu7xen6Dg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:k9Yv2KT-OzA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:lkCHfEIDCM4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:sqj_QLt3oW0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:t9OlRCaJKZQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:wvX7t50sOpM","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":11,"other":0,"podcast":7,"publication":0,"registry":0,"regulatory":0,"x_thread":93,"x_video":0,"youtube":20},"by_evidence_role":{"commentary":131},"count":131,"evidence_window":{"end":"2026-10-12","start":"2021-12-13"},"retrieval_snapshot":"2026-10-24T05:48:31.657910Z","timeline":[{"count":3,"week":"2021-W50"},{"count":1,"week":"2022-W09"},{"count":1,"week":"2022-W12"},{"count":1,"week":"2022-W20"},{"count":1,"week":"2022-W38"},{"count":1,"week":"2022-W49"},{"count":2,"week":"2022-W50"},{"count":1,"week":"2022-W51"},{"count":1,"week":"2023-W07"},{"count":2,"week":"2023-W08"},{"count":1,"week":"2023-W09"},{"count":1,"week":"2023-W22"},{"count":1,"week":"2023-W24"},{"count":4,"week":"2023-W33"},{"count":1,"week":"2023-W39"},{"count":1,"week":"2023-W40"},{"count":1,"week":"2023-W47"},{"count":1,"week":"2023-W50"},{"count":1,"week":"2023-W51"},{"count":1,"week":"2024-W09"},{"count":1,"week":"2024-W10"},{"count":1,"week":"2024-W14"},{"count":2,"week":"2024-W21"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W29"},{"count":1,"week":"2024-W32"},{"count":1,"week":"2024-W47"},{"count":1,"week":"2024-W48"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2024-W51"},{"count":1,"week":"2025-W16"},{"count":2,"week":"2025-W18"},{"count":4,"week":"2025-W21"},{"count":4,"week":"2025-W22"},{"count":7,"week":"2025-W23"},{"count":9,"week":"2025-W24"},{"count":9,"week":"2025-W25"},{"count":2,"week":"2025-W26"},{"count":2,"week":"2025-W27"},{"count":2,"week":"2025-W28"},{"count":1,"week":"2025-W29"},{"count":3,"week":"2025-W31"},{"count":2,"week":"2025-W32"},{"count":1,"week":"2025-W35"},{"count":3,"week":"2025-W36"},{"count":2,"week":"2025-W37"},{"count":7,"week":"2025-W38"},{"count":1,"week":"2025-W39"},{"count":1,"week":"2025-W40"},{"count":2,"week":"2025-W41"},{"count":2,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":2,"week":"2025-W44"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W04"},{"count":2,"week":"2026-W10"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W13"},{"count":2,"week":"2026-W15"},{"count":1,"week":"2026-W16"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W26"},{"count":1,"week":"2026-W32"},{"count":6,"week":"2026-W39"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: elranatamab","status":"unmapped"},{"brand_names":["Darzalex"],"label":"daratumumab","slug":"daratumumab"},{"brand_names":["Revlimid"],"label":"lenalidomide","slug":"lenalidomide"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"},{"brand_names":["Velcade"],"label":"bortezomib","slug":"bortezomib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"MagnetisMM-6","aliases":["MagnetisMM-6","A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant","AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA"],"brief_title":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Multiple Myeloma"],"enrollment":{"count":1060,"type":"ESTIMATED"},"interventions":[{"name":"Elranatamab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Daratumumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Lenalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Bortezomib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05623020","official_title":"AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2030-10-18","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Part 1 Dose Limiting Toxicity","timeFrame":"From the first dose of elranatamab/first full dose in combination with EDR until 28 days (+/- visit window) from the first administration of elranatamab with daratumumab and lenalidomide"},{"measure":"Part 2: Progression free survival per IMWG","timeFrame":"From randomization up to 97 months."},{"measure":"Part 2: Minimal Residual Disease negative CR rate","timeFrame":"At 12 months after randomization"}],"registry_last_updated":"2026-09-25","registry_url":"https://clinicaltrials.gov/study/NCT05623020","short_name":"MagnetisMM-6","short_name_basis":"registry_acronym","sponsor":"Pfizer","start_date":{"date":"2022-11-10","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"C1071006","type":"sponsor_study_id"},{"domain":"Alias Study Number","id":"MAGNETISMM-6","type":"other"},{"domain":"CTIS (EU)","id":"2024-514139-50-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}